MAGEA4 and synovial sarcoma: Recent clinical data from MAGE-A4–directed TCR-T cell programs have reinforced their utility: a multicenter phase 1 trial of afamitresgene autoleucel demonstrated acceptable safety and encouraging antitumor activity in patients with MAGE-A4-positive solid tumors, including synovial sarcoma [52,53].